IP Library Granted Patent US 11,033,491
Granted Patent B2
US 11,033,491 · App. 17/072,243 · Granted Jun 15, 2021

Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

Inventors: Dov Tamarkin (Maccabim, IL); Doron Friedman (Karmei Yosef, IL); Tal Berman (Rishon Le Ziyyon, IL); Enbal Ziv (Gedera, IL); David Schuz (Gimzu, IL)
Assignee: Vyne Therapeutics Inc.
A61K9/0014A01N25/16A61K8/046A61K8/34A61K8/345A61K8/362A61K8/37A61K8/42A61K8/4993A61K8/731A61K8/736A61K8/8152A61K8/8158A61K8/86A61K8/87A61K8/922A61K9/122A61Q17/02A61Q17/04A61Q19/00A61Q19/007A61Q19/02A61Q19/08A61K2800/24A61K2800/242A61K2800/244A61K2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,033,491
App. No.
17/072,243
Granted
Jun 15, 2021
Kind
B2
Abstract

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Claims (12)

1. A method of treating acne in a mammalian subject comprising administering to an afflicted body surface of the subject a foam comprising a therapeutically effective amount of a retinoid, wherein the foam is formed from a foamable carrier and a liquified or compressed propellant, the foamable carrier comprising:

i. a dicarboxylic acid ester;

ii. about 0.1% to about 5% by weight of the carrier of at least one surface-active agent;

iii. about 2% to about 50% by weight of the carrier of at least one hydrophobic solvent;

iv. water; and

v. a retinoid,

wherein the foamable carrier does not comprise a polymeric gelling agent.

2. The method of claim 1 , wherein the mammalian subject is a human.

3. The method of claim 2 , wherein the carrier is an emulsion.

4. The method of claim 3 , wherein the dicarboxylic acid ester is about 5% to about 10% by weight of the carrier.

5. The method of claim 4 , wherein the dicarboxylic acid ester is diisopropyl adipate and the at least one hydrophobic solvent is mineral oil.

6. The method of claim 5 , wherein the at least one surface-active agent has a hydrophilic/lipophilic balance (HLB) value of between about 9 and about 14.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2020
From: TAMARKIN, DOV; FRIEDMAN, DORON; BERMAN, TAL; ZIV, ENBAL; SCHUZ, DAVID
To: FOAMIX LTD.
Reel/Frame 054076/0074 →
CHANGE OF NAME Recorded Oct 16, 2020
From: FOAMIX, LTD.
To: FOAMIX PHARMACEUTICALS, LTD.
Reel/Frame 054101/0922 →
Cited By (1)
US 12,661,407